Challenges in anti-infective therapy for skin conditions: part 1

References

• Demerec M. Origin of bacterial resistance to antibiotics. J. Bacteriol.56, 63–74 (1948).
   PubMed Web of Science ®Google Scholar
• Gabel J, Levitt L, Holve E et al. Job-based health benefits in 2002: some important trends. Health Aff. (Millwood)21(5), 143–151 (2002).
   PubMed Web of Science ®Google Scholar
• 2006 Galderma Quality Report for Dermatology and Managed Care Galderma Laboratories, LP (Fort Worth, TX, USA). Kikaku America International, Washington, DC, USA (2007).
   Google Scholar
• Foxman B, Valdez RB, Lohr KN, Goldberg GA, Newhouse JP, Brook RH. The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial. J. Chronic Dis.40(5), 429–437 (1987).
   PubMedGoogle Scholar
• Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost sharing. Soc. Sci. Med.21(10), 1063–1069 (1985).
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Escarce JJ et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA291(19), 2344–2350 (2004).
   PubMed Web of Science ®Google Scholar
• Goldman DP, GF Joyce, Zheng Y. Prescription drug cost sharing. JAMA298(1), 61–69 (2007).
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff. (Millwood)25(5), 1319–1331 (2006).
   PubMed Web of Science ®Google Scholar
• Klevens RM, Morrison MA, Nadle J. Invasive methicillin-resistant Stapylococcus aureus infections in the United States. JAMA298(15), 1763–1771 (2007).
   PubMed Web of Science ®Google Scholar
• Summanen PH, Talan DA, Strong C. Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use. Clin. Infect. Dis.20(Suppl. 2), S279–S282 (1995).
   Web of Science ®Google Scholar
• Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr. Infect. Dis. J.21, 910 (2002).
   PubMed Web of Science ®Google Scholar
• Moran JG, Krishmandasan A, Gorwitz RJ. Methicillin-reistant S. aureus infections among patients in the emergency department. N. Engl. J. Med.355, 666–674 (2006).
   PubMed Web of Science ®Google Scholar
• Wiese-Posselt M, Heuck D, Draeger A, Mielke M. Successful termination of a furunculosis outbreak. Clin. Infect. Dis.44(11), e88–e95 (2007).
   PubMed Web of Science ®Google Scholar
• Miller LG, Perdreau-Remington F, Bayer AS, Diep B. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin. Infect. Dis.44(4), 471–482 (2007).
   PubMed Web of Science ®Google Scholar
• Medical Letter. New Rochelle, NY, USA 48(1228), 13 February, 2006.
   Google Scholar
• Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N. Engl. J. Med.330, 257 (1994).
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Moellering RC, Eliopoulous GM, Sande MA. The Sanford Guide to Antimicrobial Therapy (37th Edition). Antimicrobial Therapy, 16 (2007).
   Google Scholar
• Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin. Infect. Dis.44, 777–784 (2007).
   PubMed Web of Science ®Google Scholar
• Swartz MN, Pasternack MS. Cellulitis and subcutaneous tissue infections. In: Principles and Practice of Infectious Diseases (6th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone, PA, USA 1172 (2005).
   Google Scholar
• Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis.41, 1373–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Baddour LM, Bettmann MA, Bolger AF et al. Nonvalvular cardiovascular device-related infections. Circulation108, 2015–2031 (2003).
   PubMed Web of Science ®Google Scholar
• Haller PR. Infections in intravenous drug abusers. Postgrad. Med.83, 95–98 (1988).
   PubMed Web of Science ®Google Scholar
• Selinger DS, Chongsiriwatana K, Froelich CJ et al. Telltale mouth flora: a clue to the diagnosis of factitious recurrent thigh abscesses. South. Med. J.72, 225–226 (1979).
   PubMedGoogle Scholar
• Dilworth JA, Mandell GL. Adults with chronic granulomatous disease of childhood. Am. J. Med.63, 233–243 (1977).
   PubMed Web of Science ®Google Scholar
• Liese JG, Vendrossek V, Jansson A et al. Chronic granulomatous disease in adults. Lancet327, 220–223 (1995).
   Google Scholar
• The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon-γ to prevent infection in chronic granulomatous disease. N. Engl. J. Med.324, 509 (1991).
   PubMed Web of Science ®Google Scholar
• Parry MF, Root RK, Metcalf JA et al. Myeloperoxidase deficiency: prevalence and clinical significance. Ann. Intern. Med.95, 293–301 (1981).
   PubMed Web of Science ®Google Scholar
• Gallin JI. Neutrophil specific granule deficiency. Annu. Rev. Med.36, 263–274 (1985).
   PubMedGoogle Scholar
• Raz R, Miron D, Colodner R et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch. Intern. Med.156, 1109–1112 (1996).
   PubMed Web of Science ®Google Scholar
• Bakri F, Al-Hommos N, Shehabi A. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Scand. J. Infect. Dis.39(5), 457–460 (2007).
   PubMed Web of Science ®Google Scholar
• Bancroft EA. Antimicrobial resistance: it’s not just for hospitals. JAMA298(15), 1803–1804 (2007).
   PubMed Web of Science ®Google Scholar
• Medical Letter on Bioterrorism. New Rochelle, NY, USA 43 (2001).
   Google Scholar
• Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin. Infect. Dis.30(4), 684–687 (2000).
   PubMed Web of Science ®Google Scholar
• Chapman SW, Bradsher RW Jr, Campbell GD Jr et al. Practice guidelines for the management of patients with blastomycosis. Infectious Diseases Society of America. Clin. Infect. Dis.30(4), 679–683 (2000).
   PubMed Web of Science ®Google Scholar
• Ampel NM, Mosley DG, England B, Vertz PD, Komatsu K, Hajjeh RA. Coccidioidomycosis in Arizona: increase in incidence from 1990 to 1995. Clin. Infect. Dis.27(6), 1528–1530 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infect. Am. J. Med.53(3), 315–22 (1972).
   PubMed Web of Science ®Google Scholar
• Chu JH, Feudtner C, Heydon K et al. Hospitalizations for endemic mycoses: a population-based national study. Clin. Infect. Dis.42, 822 (2006).
   PubMed Web of Science ®Google Scholar
• Swiggum SM, Adam JE. Cutaneous fungal diseases in the elderly. Geriatr. Consultant10, 22–29 (1993).
   Google Scholar
• Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J. Am. Acad. Dermatol.34(2 Pt 1), 282–286 (1996).
   PubMed Web of Science ®Google Scholar
• Savin R. Diagnosis and treatment of tinea versicolor. J. Fam. Pract.43(2), 127–132 (1996).
   PubMed Web of Science ®Google Scholar
• Silva-Lizama E. Tinea versicolor. Int. J. Dermatol.34(9), 611–617 (1995).
   PubMedGoogle Scholar
• Assaf RR, Weil ML. The superficial mycoses. Dermatol. Clin.14(1), 57–67 (1996).
   PubMedGoogle Scholar
• Faergemann J. Pityrosporum infections. J. Am. Acad. Dermatol.31(3 Pt 2), S18–S20 (1994).
   Google Scholar
• Farschian M, Yaghoobi R, Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J. Dermatolog. Treat.13(2), 73–76 (2002).
   PubMed Web of Science ®Google Scholar
• Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine: a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin. Exp. Dermatol.14, 124–127 (1989).
   PubMed Web of Science ®Google Scholar
• Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology194(Suppl. 1), 22–24 (1997).
   PubMedGoogle Scholar
• Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J. Am. Acad. Dermatol.34, 785–787 (1996).
   PubMed Web of Science ®Google Scholar
• Van Cauteren H, Lampo A, Vandenberghe J et al. Safety aspects of oral antifungal agents. Br. J. Clin. Pract.(Suppl. 71), 47–49 (1990).
   Google Scholar
• Borgers M, Van den Bossche H, DeBrabander M. The mechanism of action of the new antimycotic ketoconazole. Am. J. Med.74(1B), 2–8 (1983).
   PubMedGoogle Scholar
• Schwartz RA. Superficial fungal infections. Lancet364(9440), 1173–1182 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen T. Dermatophytosis: diagnostic pointers and therapeutic pitfalls. Consultant1545–1547 (1997).
   Google Scholar
• Greenberg HL, Shwayder TA, Bieszk N, Fivenson DP. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr. Dermatol.19(1), 78–81 (2002).
   PubMedGoogle Scholar
• Wingfield AB, Fernandez-Obregon AC, Wignall FS, Greer DL. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. Br. J. Dermatol.150, 119–126 (2004).
   PubMedGoogle Scholar
• Webster SB. How I manage jock itch. Phys. Sportsmed.12(5), 109–113 (1984).
   PubMedGoogle Scholar
• Holdiness MR. Management of cutaneous erythrasma. Drugs62, 1131–1141 (2002).
   PubMedGoogle Scholar
• Montero-Gei F, Perera A. Therapy with fluconazole for tinea corporis, tinea cruris, and tinea pedis. Clin. Infect. Dis.14(Suppl.), S77–S81 (1992).
   Web of Science ®Google Scholar
• Faergemann J, Mörk NJ, Haglund A, Ödegård T. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br. J. Dermatol.136, 575–577 (1997).
   PubMed Web of Science ®Google Scholar
• Pariser DM, Pariser RJ, Ruoff G, Ray TL. Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. J. Am. Acad. Dermatol.31, 232–234 (1994).
   PubMed Web of Science ®Google Scholar
• Farag A, Taha M, Halim S. One week therapy with oral terbinafine in cases of tinea cruris/corporis. Br. J. Dermatol.131, 684–686 (1994).
   PubMed Web of Science ®Google Scholar
• Brooks KE, Bender JF. Tinea pedis: diagnosis and treatment. Clin. Podiatr. Med. Surg.13(1), 31–46 (1996).
   PubMedGoogle Scholar
• Masri-Fridling GD. Dermatophytosis of the feet. Dermatol. Clin.14(1), 33–40 (1996).
   PubMed Web of Science ®Google Scholar
• Lescher JL. Oral therapy of common superficial fungal infections of the skin. J. Am. Acad. Dermatol.40(6), S31–S34 (1999).
   Google Scholar
• Del Aguila R, Gei FM, Robles M, Perera-Ramirez A, Male O. Once weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. Clin. Exp. Dermatol.17, 402–406 (1992).
   PubMedGoogle Scholar
• Gupta AK, DeDoncker P, Heremans A et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J. Am. Acad. Dermatol.36, 789–792 (1997).
   PubMed Web of Science ®Google Scholar
• Schwartz RA, Janniger CK. Tinea capitis. Cutis55(1), 29–33 (1995).
   PubMed Web of Science ®Google Scholar
• Howard R, Frieden IJ. Tinea capitis: new perspectives on an old disease. Semin. Dermatol.14(1), 2–8 (1995).
   PubMedGoogle Scholar
• Elewski B. Tinea capitis. Dermatol. Clin.14(1), 23–31 (1996).
   PubMedGoogle Scholar
• Elewski BE, Hay RJ. International summit on cutaneous antifungal therapy, focus on tinea capitis, Boston, Massachusetts, November 11–13, 1994. Pediatr. Dermatol.13(1), 69–77 (1996).
   PubMedGoogle Scholar
• Emanuel D, McNeely MC. Tinea faciei. Hosp. Med.12 (1996).
   Google Scholar
• Karakas M, Baba M, Aksungur VL et al. Manifestation of cellulitis after saphenous venectomy for coronary bypass surgery. J. Eur. Acad. Dermatol. Venereol.16(5), 438–440 (2002).
   PubMedGoogle Scholar
• Andre J, Berger T, De Doncker P et al. The second international symposium on onychomycosis: an update on the issues. Med. Monitor.2(1), 1–8 (1996).
   Google Scholar
• Hay RJ. Yeast infections. Dermatol. Clin.14(1), 113–124 (1996).
   PubMedGoogle Scholar
• Roberts DT. Onychomycosis: current treatment and future challenges. Br. J. Dermatol.141(Suppl. 56), 1–4 (1999).
   PubMed Web of Science ®Google Scholar
• Turner DR, Nagra RS, Large S, Seaton D. Recurrent cellulitis following coronary bypass surgery. J. Hosp. Infect.30(1), 78–80 (1995).
   PubMedGoogle Scholar
• Björnsdóttir S, Gottfredsson M, Thórisdóttir AS, Gunnarsson GB. Risk factors for acute cellulitis of the lower limb: a prospective case–control study. Clin. Infect. Dis.41(10), 1416–1422 (2005).
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case–control study. Dermatology209(4), 301–307 (2004).
   PubMed Web of Science ®Google Scholar
• Cirillo-Hyland V, Humphreys T, Elenitsas R. Tinea faciei. J. Am. Acad. Dermatol.29(1), 119–120 (1993).
   PubMedGoogle Scholar
• Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr. Infect. Dis. J.20(2), 197–206 (2005).
   Google Scholar
• American Academy of Dermatology. Guidelines of care for superficial mycotic infections of the skin: mucocutaneous candidiasis. Guidelines/outcome committee. American Academy of Dermatology. J. Am. Acad. Dermatol.34(1), 110–115 (1996).
   PubMedGoogle Scholar
• Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol.57(5), 737–763 (2007).
   PubMed Web of Science ®Google Scholar
• Ribes J, Steele A, Seabolt J, Baker D. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J. Clin. Microbiol.39, 3321–3325 (2001).
   PubMedGoogle Scholar
• Corey L, Spear PG. Infections with herpes simplex viruses (1). N. Engl. J. Med.314, 686–691 (1986).
   PubMed Web of Science ®Google Scholar
• Spruance SL. The natural history of recurrent oro-facial herpessimplex virus infection. Semin. Dermatol.11, 200–206 (1992).
   PubMedGoogle Scholar
• Miller MF, Ship II. A retrospective study of the prevalence and incidence of recurrent aphthous ulcers in a professional population, 1958–1971. Oral Surg. Oral Med. Oral Pathol.43, 532–537 (1977).
   PubMedGoogle Scholar
• Knipe DM, Roizman B. Herpes simplex viruses and their replication. In: Fields Virology (4th Edition). Knipe DM, Howley PM, Griffin DE et al. (Eds). Lippincott Williams and Wilkins, PA, USA 2399–2460 (2001).
   Google Scholar
• Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus type 2 and 1: a global review. J. Infect. Dis.186(Suppl. 1), S3–S28 (2002).
   PubMed Web of Science ®Google Scholar
• Wheeler CE. The herpes simplex problem. J. Am. Acad. Dermatol.18, 163–168 (1988).
   PubMed Web of Science ®Google Scholar
• Nahmias AJ, Lee FK, Beckman-Nahimas S. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis.69(Suppl.), 19–36 (1990).
   Google Scholar
• Strauss S. Introduction of herpesviridae. In: Principles and Practice of Infectious Diseases (5th Edition). Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingstone, PA, USA 1557–1580 (2000).
   Google Scholar
• Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: a review. Int. J. Epidemiol.26, 698–709 (1997).
   PubMedGoogle Scholar
• Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet357, 1513–1518 (2001).
   PubMed Web of Science ®Google Scholar
• Ohana B, Lipson M, Vered N, Srugo I, Ahdut M, Morag A. Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies. Clin. Diagn. Lab. Immunol.7, 904–908 (2000).
   PubMedGoogle Scholar
• Flemning D, McQuillan G, Johnson R et al. Herpes simplex virus type 2 in the United States, 1976–1994. N. Engl. J. Med.337, 1105–1111 (1997).
   PubMedGoogle Scholar
• Mertz G, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med.116, 197–202 (1992).
   PubMed Web of Science ®Google Scholar
• Beauman JG. Genital herpes: a review. Am. Fam. Physician72, 1527–1534 (2005).
   PubMed Web of Science ®Google Scholar
• Kleymann G. Novel agents and strategies to treat herpes simplex virus infections. Expert Opin. Investig. Drugs12, 165–183 (2003).
   PubMed Web of Science ®Google Scholar
• Brady R, Bernstein D. Treatment of herpes simplex infections. Antiviral Res.61, 73–81 (2004).
   PubMedGoogle Scholar
• Leflore S, Anderson PL, Fletcher CV. A risk–benefit evaluation of acyclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf.23, 131–142 (2000).
   PubMedGoogle Scholar
• Greenberg MS. Herpesvirus infections. Dent. Clin. North Am.40, 359–368 (1996).
   PubMedGoogle Scholar
• Brown TJ, Vander Straten M, Tyring SK. Systemic dermatologic therapy: antiviral agents. Dermatol. Clin.19, 23–34 (2001).
   PubMed Web of Science ®Google Scholar
• Turner R, Shehab Z, Osborne K, Hendley JO. Shedding and survival of herpes simplex virus from ‘fever blisters’. Pediatrics70, 547–549 (1982).
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Embil JA. Herpes simplex virus infection: what to look for? What to do! J. Can. Dent. Assoc.56, 785–787 (1990).
   PubMedGoogle Scholar
• Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes11(Suppl. 3), 130A–137A (2004).
   Google Scholar
• Fillet AM. Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients. Drugs Aging19, 343–354 (2002).
   PubMedGoogle Scholar
• Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex infection. Influence of site of infection and viral type. N. Engl. J. Med.316, 1444–1449 (1987).
   PubMed Web of Science ®Google Scholar
• Simmons A. Clinical manifestations and treatment considerations of herpes simplex virus infection. J. Infect. Dis.186(Suppl. 1), S71–S77 (2002).
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin. Infect. Dis.26, 541–553 (1998).
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Gnann JW. The epidemiology and clinical manifestations of herpes simplex virus infections. In: The Human Herpesviruses. Roizman B, Whitley RJ, Lopez C (Ed.). Raven Press, NY, USA 69–105 (1993).
   Google Scholar
• Lafferty W. The challenging epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes9, 51–55 (2002).
   PubMedGoogle Scholar
• Xu F, Sternberg MR, Kottiri BJ, McQuillan GM. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA296, 964–973 (2006).
   PubMed Web of Science ®Google Scholar
• Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: a review. Int. J. Epidemiol.26, 698–709 (1997).
   PubMedGoogle Scholar
• Corey L, Adams H, Brown Z, Holmes K. Genital herpes simplex virus infections: clinical manifestations, course and complications. Ann. Intern. Med.98, 958–972 (1983).
   PubMed Web of Science ®Google Scholar
• Ashley R, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin. Microbiol. Rev.12, 1–8 (1999).
   PubMed Web of Science ®Google Scholar
• Sacks SL, Wilson BR. Genital herpes: management issues for the next century. Antivir. Chem. Chemother.8(Suppl. 1), 45–50 (1997).
   Google Scholar
• Lafferty W. The challenging epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes9, 51–55 (2002).
   PubMedGoogle Scholar
• Wald A, Zeh S, Selke R, Ashley R, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med.333, 770–775 (1995).
   PubMed Web of Science ®Google Scholar
• Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med.121, 847–854 (1994).
   PubMed Web of Science ®Google Scholar
• Docherty J, Trimble J, Roman S et al. Lack of oral HSV-2 in a college student population. J. Med. Virol.16, 283–287 (1985).
   PubMedGoogle Scholar
• Nadelman CM, Newcomer VD. Herpes simplex virus infections. Postgrad. Med.107, 189–200 (2000).
   PubMed Web of Science ®Google Scholar
• Corey L. The current trend in genital herpes: progress in prevention. Sex. Transm. Dis.21(Suppl. 2), S38–S44 (1994).
   Google Scholar
• Kinghorn G. Epidemiology of genital herpes. J. Int. Med. Res.22(Suppl. 1), 14A–23A (1994).
   Google Scholar
• Spruance SL. Herpes simplex labialis. In: Clinical Management of Herpes Viruses. Sacks SL, Straus SE, Whitley RJ, Griffith PD (Eds). IOS Press, Amsterdam, The Netherlands 3–42 (19951995).
   Google Scholar
• Koelle D, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann. Intern. Med.116, 433–437 (1992).
   PubMed Web of Science ®Google Scholar
• Sacks S, Griffiths P, Corey L et al. HSV shedding. Antiviral Res.63(Suppl. 1), S19–S26 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts C. Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Herpes12, 10–14 (2005).
   PubMedGoogle Scholar
• Wald A, Zeh J, Selke S et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med.342, 844–850 (2000).
   PubMed Web of Science ®Google Scholar
• Mertz G, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med.116, 197–202 (1992).
   PubMed Web of Science ®Google Scholar
• Goldman B. Herpes serology for dermatologists. Arch. Dermatol.136, 1158–1161 (2000).
   PubMedGoogle Scholar
• Brown TJ, McCrary M, Tyring SK. Antiviral agents: nonantiviral drugs. J. Am. Acad. Dermatol.47, 581–599 (2002).
   PubMed Web of Science ®Google Scholar
• Frenkel L, Garratty E, Shen J, Wheeler N, Clark O, Bryson Y. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann. Intern. Med.118, 414–418 (1993).
   PubMedGoogle Scholar
• Esmann J. The many challenges of facial herpes simplex virus infection. J. Antimicrobiol. Chem.47, 17–27 (2001).
   PubMedGoogle Scholar
• Marcus B, Lipozencic J, Mafz H, Orion E, Wolf R. Herpes simplex: autoinoculation versus dissemination. Acta Dermatovenerol. Croat.13, 237–241 (2005).
   PubMedGoogle Scholar
• Stone KM, Brooks CA, Guinan ME, Alexander ER. National surveillance for neonatal herpes simplex infections. Sex. Transm. Dis.16, 152–156 (1989).
   PubMed Web of Science ®Google Scholar
• Rudnick C, Hoekzema G. Neonatal herpes simplex virus infections. Am. Fam. Physician65, 1138–1142 (2002).
   PubMed Web of Science ®Google Scholar
• Whitley RJ. Herpes simplex virus infections of women and their offspring: implications for a developed society. Proc. Natl Acad. Sci. USA91, 2441–2447 (1994).
   PubMedGoogle Scholar
• ACOG Practice Bulletin. Clinical management guidelines obstetrician–gynecologists. Number 57. Gynecologic herpes simplex virus infections. Obstet. Gynecol.104, 1111–1117 (2004).
   PubMedGoogle Scholar
• Habif T. The Diagnostic Manual of Herpesvirus Infections. Burroughs Welcome Co., Research Triangle Park, NC, USA (1995).
   Google Scholar
• Brown ZA, Selke S, Zeh J et al. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med.337, 509–515 (1997).
   PubMed Web of Science ®Google Scholar
• Brown Z, Benedetti J, Ashley R et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N. Engl. J. Med.324, 1247–1252 (1991).
   PubMed Web of Science ®Google Scholar
• Whitley R. Neonatal herpes simplex virus infection. Curr. Opin. Infect. Dis.17, 243–246 (2004).
   PubMed Web of Science ®Google Scholar
• Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet. Gynecol.87(1), 69–73 (1996).
   PubMed Web of Science ®Google Scholar
• Smith JR, Cowan FM, Munday P. The management of herpes simplex infections in pregnancy. Br. J. Obstet. Gynecol.105, 255–260 (1998).
   PubMedGoogle Scholar
• American Academy of Pediatrics Committee on Fetus and Newborn. Standards and Recommendations of Hospital Care of Newborn Infants (6th Edition). American Society of Pediatrics, IL, USA (1977).
   Google Scholar
• Brown Z. Genital herpes complicating pregnancy. Dermatol. Clin.16, 805–810 (1998).
   PubMedGoogle Scholar
• Brown Z, Wald A, Morrow R, Selke S, Zeh J, Corey L. Effect of serologic status and caesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA289, 203–209 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrante P, Mancuso R, Pagani E et al. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. J. Neurol. Virol.6(Suppl. 2), S109–S114 (2000).
   Google Scholar
• Bale JF. Viral encephalitis. Med. Clin. North Am.77, 25–42 (1993).
   PubMed Web of Science ®Google Scholar
• Bork K, Brauninger W. Increasing incidence of eczema herpeticum: an analysis of seventy-five cases. J. Am. Acad. Dermatol.19, 1024–1029 (1988).
   PubMedGoogle Scholar
• Nikkles A, Pierard G. Treatment of mucocutaneous presentations of herpes simplex infections. Am. J. Clin. Dermatol.3, 475–487 (2002).
   PubMedGoogle Scholar
• Mooney MA, Janniger CK, Schwartz RA. Kaposi’s varicelliform eruption. Cutis53, 243–245 (1994).
   PubMedGoogle Scholar
• Nadelman CM, Newcomer VD. Herpes simplex virus infections. Postgrad. Med.107, 189–200 (2000).
   PubMed Web of Science ®Google Scholar
• Anderson B. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin. J. Sport Med.9, 86–90 (1999).
   PubMed Web of Science ®Google Scholar
• Corey L, Spear PG. Infections with herpes simplex viruses. N. Engl. J. Med.314, 686–691 (1986).
   PubMed Web of Science ®Google Scholar
• Feder H, Long S. Herpetic whitlow. Epidemiology, clinical characteristics, diagnosis, and treatment. Am. J. Dis. Child.137, 861–863 (1983).
   PubMedGoogle Scholar
• Gill M, Arlette J, Buchan K. Herpes simplex virus infection of the hand: a profile of 79 cases. Am. J. Med.84, 89–93 (1988).
   PubMedGoogle Scholar
• Gill M, Arlette J, Buchan K. Herpes simplex virus infection of the hands. J. Am. Acad. Dematol.22, 111–116 (1990).
   PubMedGoogle Scholar
• Patel R. Progress in meeting today’s demands in genital herpes: an overview of current management. J. Infect. Dis.186(Suppl.), 847–856 (2002).
   PubMedGoogle Scholar
• Nadal SR, Calore EE, Manzione CR, Horta S, Ferreira A, Almeida L. Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis. Colon Rectum48, 2289–2293 (2005).
   PubMedGoogle Scholar
• Carrasco DA, Trizna Z, Colone-Grimmer M, Tyring SK. Verrucous herpes of the scrotum in a human immunodeficiency virus-positive man: case report and review of the literature. J. Eur. Acad. Dermatol. Venereol.16, 511–515 (2002).
   PubMedGoogle Scholar
• Beasley KL, Cooley GE, Kao GF, Lowitt MH, Burnett JW, Aurelian L. Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency. J. Am. Acad. Dermatol.37, 860–863 (1997).
   PubMedGoogle Scholar
• Mlynarczyk B, Majewski S. Pathogenesis and treatment of herpes simplex and herpes varicella–zoster virus infections. Przegl Dermatol.89, 133–138 (2002).
   Google Scholar
• Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br. J. Dermatol.128, 542–545 (1993).
   PubMed Web of Science ®Google Scholar
• Livneh A, Shemer J, Danon YL, Peretz B. Herpes simplex associated erythema multiforme (HAEM), a clinical therapeutic dilemma. Pediatr. Dent.21, 359–362 (1999).
   PubMedGoogle Scholar
• Drago F, Parodi A, Rebora A. Persistent erythema multiforme: report of two new cases and review of literature. J. Am. Acad. Dermatol.33, 366–369 (1995).
   PubMedGoogle Scholar
• Bhushan M, Craven N. Erythema multiforme. In: Treatment of Skin Disease: Comprehensive Therapeutic Strategies. Lebwohl M, Heymann W, Berth-Jones J, Coulson I (Eds). Mosby, London, UK 196–199 (2002).
   Google Scholar
• Kokuba S, Imafuku S, Huang S, Burnett J. Expression of a herpes simplex virus (HSV) gene and the qualitative nature of the HSV-specific T cell response are associated with the development of erythema multiforme lesions. Br. J. Dermatol.138, 952–964 (1998).
   PubMedGoogle Scholar
• Aurelian L, Ono F, Sharma B, Smith C, Burnett J. CD34+ cells in the peripheral blood transport herpes simplex virus (HSV) DNA fragments to the skin of patients with erythema multiforme (HAEM). J. Invest. Dermatol.14, 1215–1224 (2005).
   Google Scholar
• Mahendran R, Grant JW, Norris PG. Dapsone-reponsive persistent erythema multiforme. J. Dermatol.200, 281–282 (2000).
   Google Scholar
• Huber MA. Herpes simplex type-1 virus infection. Quintessence Int.34, 453–467 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm. Rep.51, 1–78 (2002).
   Web of Science ®Google Scholar
• Wright EF. Clinical effectiveness of lysine in treating recurrent aphthous ulcers and herpes labialis. Gen. Dent.42, 40–42 (1994).
   PubMedGoogle Scholar
• Bisaccia E, Scarborough D. Herpes simplex virus prophylaxis with famciclovir in patients undergoing aesthetic facial CO2 laser resurfacing. Cutis72, 327–328 (2003).
   PubMedGoogle Scholar
• Gilbert S. Improving the outcome of facial resurfacing. J. Antimicrob. Chemother.47(Suppl. T1), 29–34 (2001).
   PubMedGoogle Scholar
• Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol. Surg.26, 50–54 (2000).
   PubMed Web of Science ®Google Scholar
• Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother.47(3), 1072–1080 (2003).
   PubMed Web of Science ®Google Scholar
• Hull C, Spruance S, Tyring S, Hamed K. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother.47(3), 1072–1080 (2003).
   PubMedGoogle Scholar
• Baker D, Deeler R, Redder K, Phillips J. Valacyclovir effective for suppression of recurrent HSV-1 herpes labialis. In: Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. American Society for Microbiology, Washington, DC, USA, 263 (2002) (Abstract 464).
   Google Scholar
• Stanberry L, Cunningham A, Mertz G et al. New developments in the epidemiology, natural history and management of genital herpes. Antiviral Res.42, 1–14 (1999).
   PubMed Web of Science ®Google Scholar
• Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch. Virol.148, 1757–1769 (2003).
   PubMed Web of Science ®Google Scholar
• Romanowski B. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice daily episodic therapy for recurrent genital herpes. Sex. Transm. Dis.30, 226–231 (2003).
   PubMed Web of Science ®Google Scholar
• Patel R, Tyring S, Strand A, Price M, Grant D. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex. Transm. Infect.75, 398–402 (1999).
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Pang K, Wu J et al. Emerging therapies for herpes viral infections (types 1–8). Expert Opin. Emerg. Drugs9, 237–256 (2004).
   PubMedGoogle Scholar
• Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. J. Clin. Invest.99, 1097 (1997).
   Google Scholar
• Wald A, Zeh J, Barnum G, Davis L, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med.124, 8–15 (1996).
   PubMed Web of Science ®Google Scholar
• Corey L. Challenges in genital herpes simplex virus management. J. Infect. Dis.186(Suppl. 1), S29–S33 (2002).
   Google Scholar
• Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster and post herpetic neuralgia. Am. Fam. Physician61, 2437–2444, 2447–2448 (2000).
   PubMed Web of Science ®Google Scholar
• Narkeviciute I. Consequences of varicella in pregnancy: a report of four cases. Acta Paediatr.96(7), 1099–1100 (2007).
   PubMedGoogle Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch. Intern. Med.155, 1605–1609 (1995).
   PubMed Web of Science ®Google Scholar
• Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J. Infect. Dis.171, 701–704 (1995).
   PubMed Web of Science ®Google Scholar
• Brody MB, Moyer D. Varicella–zoster virus infection. Postgrad. Med.102(1), 187–194 (1997).
   PubMed Web of Science ®Google Scholar
• Smith JB, Fenske NA. Herpes zoster and internal malignancy. South. Med. J.88, 1089–1092 (1995).
   PubMed Web of Science ®Google Scholar
• Strauss SE. Overview: the biology of varicella–zoster virus infection. Ann. Neurol.35(Suppl.), S4–S8 (1994).
   Google Scholar
• Kost RG, Stranb SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N. Engl. J. Med.335, 32–42 (1996).
   PubMed Web of Science ®Google Scholar
• Schmader K. Management of herpes zoster in elderly patients. Infect. Dis. Clin. Pract.4, 293–299 (1995).
   Web of Science ®Google Scholar
• Whitley RJ, Weiss H, Gnann J et al. Acylclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann. Intern. Med.125, 376–383 (1996).
   PubMed Web of Science ®Google Scholar
• Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA211, 1681–1683 (1970).
   PubMed Web of Science ®Google Scholar
• Keczkes K, Basheer AM. Do corticosteroids prevent post-herpetic neuralgia? Br. J. Dermatol.102, 551–555 (1980).
   PubMed Web of Science ®Google Scholar
• Esmann V, Geil JP, Kroon S et al. Prednisolone does not prevent post-herpetic neuralgia. Lancet2(8551), 126–129 (1987).
   PubMed Web of Science ®Google Scholar
• Lee PJ, Annunziato P. Current management of herpes zoster. Infect. Med.15, 709–713 (1998).
   Google Scholar
• MacFarlane BV, Wright A, O’Callaghan J, Benson HA. Chronic neuropathic pain and its control by drugs. Pharmacol. Ther.75, 1–19 (1997).
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain65, 39–44 (1996).
   PubMed Web of Science ®Google Scholar
• Brisson M, Gay N, Edmunds W, Andrews N. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chicken pox. Vaccine20(19–20), 2500–2507 (2002).
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med.253(22), 2271–2284 (2005).
   Google Scholar
• Yih WK, Brooks DR, Lett SM, Jumaan AO. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccination coverage, 1998–2003. BMC Public Health5(1), 68 (2005).
   PubMed Web of Science ®Google Scholar
• Goldman GS. Universal varicella vaccination: efficacy trends and effect on herpes zoster. Int. J. Toxicol.24(4), 205–213 (2005).
   PubMedGoogle Scholar
• Thomas SL, Wheeler JG, Hall AJ. Micronutrient intake and the risk of herpes zoster: a case–control study. Int. J. Epidemiol.35(2), 307–314 (2006).
   PubMedGoogle Scholar
• Irwin MR, Olmstead R, Oxman MN. augmenting immune responses to varicella zoster virus in older adults: a randomized, controlled trial of tai chi. J. Am. Geriatr. Soc.55(4), 511–517 (2007).
   PubMed Web of Science ®Google Scholar
• Tyring S. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J. Am. Acad. Dermatol.43(1), S18–S26 (2000).
   Google Scholar
• de Villiers EM, Papillomavirus and HPV typing. Clin. Dermatol.15, 199–206 (1997).
   PubMed Web of Science ®Google Scholar
• Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV inections among females attributable to trichomoniasis in the US. Sex. Transm. Dis.31(9), 547–551 (2004).
   PubMed Web of Science ®Google Scholar
• Dixon FJ, Milanova T, Beusterien K. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. J. Am. Geriatr. Soc.196(3), 206–212 (2007).
   Google Scholar
• Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am. J. Obstet. Gynecol.189(3 Suppl.), S3–S11 (2003).
   Web of Science ®Google Scholar
• Syed TA, Lundin S, Ahmad SA. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study. Dermatology189, 142–145 (1994).
   PubMed Web of Science ®Google Scholar
• Nelson L. The importance of patient and healthcare provider perceptions in the evaluation of imiquimod and other prior treatments for anogenital warts. Int. J. STD AIDS13, 29–35 (2002).
   PubMedGoogle Scholar
• Department of Health and Human Services. Centers for Disease Control and Prevention. Sexually transmitted diseases, treatment guidelines. Atlanta, USA. Morb. Mortal. Wkly Rep.51 (2002).
   Google Scholar
• Gellin B, Modlin JF, Barr E, Tamms G (Eds). Quadrivalent human papillomavirus vaccine. Clin. Infect. Dis.45(5), 609–607 (2007).
   PubMedGoogle Scholar
• Eastman P. New report from George Washington University recommends that HPV vaccination should be required by state mandate. Oncology Times29(4), 30–31 (2007).
   Google Scholar
• Saslow D, Castle PE, Cox JT, Davey DD. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin.57, 7–28 (2007).
   PubMed Web of Science ®Google Scholar